Prosecutors said laboratory and medical records were altered to justify DNA testing billed to Medicare and Medicaid. The case is part of a kickback-and-bribery network that helped drive more than $522 million in alleged fraudulent claims.

The DOJ said the genetic testing scheme depended on more than just improper patient targeting—it also used documentation manipulation to make billing look medically defensible. In the alleged model, patients were allegedly recruited through “marketers” who provided illegal kickbacks and bribes in connection with obtaining DNA samples. DOJ then claimed that laboratory and medical records were falsified to create the impression that the tests were clinically warranted. That documentation, prosecutors said, was used to support claims submissions for genetic tests that were allegedly medically unnecessary. By coupling fraudulent intake with record falsification, the scheme attempted to bypass safeguards in health-care coverage and reimbursement processes for Medicare and Medicaid, as well as insured individuals. DOJ highlighted the scale of the alleged harm, stating the scheme resulted in more than $522 million in fraudulent claims. The sentencing signals that federal prosecutors will pursue not only the financial steering mechanisms of health-care fraud, but also the downstream record fabrication that ties patient data to reimbursement. For consumers and providers, the case illustrates how fake medical justification can be used to turn genetic testing marketing into large reimbursement losses.